olprinone has been researched along with Cardiac Failure in 17 studies
olprinone: RN refers to HCl; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study Olprinone, milrinone, PDE inhibitors, cardiac failure, and HF were selected as the search terms to retrieve articles published between January 1999 and March 2022." | 9.41 | Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure. ( Fu, Y; Pan, Y; Wang, X; Zhang, H, 2023) |
| "We investigated the short-term effects of a phosphodiesterase III inhibitor (Olprinone) on hemodynamics and thoracic duct lymph flow in anesthetized open-chest sheep with heart failure induced by endothelin-1 (cardiogenic shock)." | 7.71 | Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1. ( Inagaki, M; Ishikawa, S; Mitsui, T; Onizuka, M; Sato, Y; Tomoyasu, M; Yamamoto, T, 2002) |
| "We examined the effects of a novel phosphodiesterase III inhibitor, olprinone, on the cardiohemodynamics and plasma hormones in conscious pigs with pacing-induced heart failure." | 7.69 | Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure. ( Adachi, H; Tanaka, H, 1997) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 5.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| " In this study Olprinone, milrinone, PDE inhibitors, cardiac failure, and HF were selected as the search terms to retrieve articles published between January 1999 and March 2022." | 5.41 | Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure. ( Fu, Y; Pan, Y; Wang, X; Zhang, H, 2023) |
| "We investigated the short-term effects of a phosphodiesterase III inhibitor (Olprinone) on hemodynamics and thoracic duct lymph flow in anesthetized open-chest sheep with heart failure induced by endothelin-1 (cardiogenic shock)." | 3.71 | Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1. ( Inagaki, M; Ishikawa, S; Mitsui, T; Onizuka, M; Sato, Y; Tomoyasu, M; Yamamoto, T, 2002) |
| "We examined the effects of a novel phosphodiesterase III inhibitor, olprinone, on the cardiohemodynamics and plasma hormones in conscious pigs with pacing-induced heart failure." | 3.69 | Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure. ( Adachi, H; Tanaka, H, 1997) |
| "Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties." | 2.41 | Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. ( Mizushige, K; Suzuki, H; Ueda, T; Yukiiri, K, 2002) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 1.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| "After the production of mitral regurgitation by transmyocardial chordal sectioning and obtaining a stable state, dopamine (5 micrograms/kg/min) was infused until the peak positive dP/dt (peak (+) dP/dt) increased to about 50% of the predopamine value." | 1.28 | Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs. ( Hayashi, M; Himura, Y; Kawai, C; Kumada, T; Nakamura, Y; Tanio, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y | 1 |
| Wang, X | 1 |
| Pan, Y | 1 |
| Zhang, H | 1 |
| Dobashi, S | 1 |
| Watanabe, I | 1 |
| Nakanishi, R | 1 |
| Hisatake, S | 1 |
| Kiuchi, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Fujii, T | 1 |
| Ikeda, T | 1 |
| Murata, H | 1 |
| Inoue, H | 1 |
| Sumikawa, K | 1 |
| Nishi, K | 1 |
| Sato, Y | 2 |
| Miyamoto, T | 1 |
| Toma, M | 1 |
| Taniguchi, R | 1 |
| Fukuhara, R | 1 |
| Saijo, S | 1 |
| Fujiwara, H | 1 |
| Takatsu, Y | 1 |
| Mizushige, K | 2 |
| Ueda, T | 2 |
| Yukiiri, K | 2 |
| Suzuki, H | 1 |
| Tomoyasu, M | 1 |
| Onizuka, M | 1 |
| Inagaki, M | 1 |
| Yamamoto, T | 1 |
| Ishikawa, S | 1 |
| Mitsui, T | 1 |
| Takahashi, T | 1 |
| Kohno, M | 1 |
| Goto, Y | 2 |
| Honda, M | 1 |
| Kuramochi, T | 1 |
| Ishinaga, Y | 1 |
| Kuzuo, H | 1 |
| Tanaka, K | 1 |
| Morioka, S | 1 |
| Enomoto, K | 1 |
| Takabatake, T | 1 |
| Holubarsch, C | 1 |
| Adachi, H | 1 |
| Tanaka, H | 1 |
| Kanda, M | 1 |
| Yasuda, S | 1 |
| Sumida, H | 1 |
| Baba, T | 1 |
| Noguchi, T | 1 |
| Nonogi, H | 1 |
| Nakamura, T | 1 |
| Suzuki, S | 1 |
| Ushiyama, C | 1 |
| Shimada, N | 1 |
| Koide, H | 1 |
| Ohhara, H | 2 |
| Sawada, K | 1 |
| Ogawa, T | 2 |
| Takeda, M | 2 |
| Igarashi, T | 2 |
| Tanio, H | 1 |
| Kumada, T | 1 |
| Hayashi, M | 1 |
| Himura, Y | 1 |
| Nakamura, Y | 1 |
| Kawai, C | 1 |
| Sasayama, S | 1 |
| Asanoi, H | 1 |
| Ishizaka, S | 1 |
| Katoh, H | 1 |
| Daiku, Y | 1 |
3 reviews available for olprinone and Cardiac Failure
| Article | Year |
|---|---|
Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure.
Topics: Heart Failure; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones | 2023 |
Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects.
Topics: Carotid Arteries; Cerebrovascular Circulation; Heart Failure; Humans; Imidazoles; Muscle, Smooth, Va | 2002 |
[How to use PDE III inhibitors].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Blood Pressure; Cyclic Nucleotide Phosphodiester | 2007 |
2 trials available for olprinone and Cardiac Failure
| Article | Year |
|---|---|
Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cerebral Cortex; Cerebrovascular Circulation; Female; Heart | 2003 |
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Topics: Adult; Cardiotonic Agents; Endothelin-1; Female; Heart Failure; Humans; Imidazoles; Male; Middle Age | 2002 |
12 other studies available for olprinone and Cardiac Failure
| Article | Year |
|---|---|
Comparing the effects of milrinone and olprinone in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Hospitaliza | 2020 |
Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery.
Topics: Anesthesia; Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Artery Bypass; Gastroepiploic Arter | 2010 |
Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Female; F | 2012 |
Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiac Output; Central Venous Pressure; Cyclic Nucleo | 2002 |
Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calcium; Cyclic AMP; Cyclic Nucleotide Phosphodiestera | 1994 |
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failur | 1997 |
Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Pressure; Cardiotonic Agents; Cyclic AMP; Cyclic | 1997 |
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Amrinone; Creatinine; Diuresis; Female; Follow-Up Studies; Heart Failure; H | 1999 |
[Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes].
Topics: Action Potentials; Animals; Atrioventricular Node; Cardiotonic Agents; Dogs; Dose-Response Relations | 1992 |
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
Topics: Acute Disease; Animals; Cardiotonic Agents; Dogs; Dopamine; Heart Failure; Hemodynamics; Imidazoles; | 1991 |
Mechanics of contraction and relaxation of the ventricle in experimental heart failure produced by rapid ventricular pacing in the conscious dog.
Topics: Animals; Cardiac Pacing, Artificial; Dobutamine; Dogs; Heart Failure; Imidazoles; Myocardial Contrac | 1991 |
Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
Topics: Anesthesia; Animals; Cardiotonic Agents; Coronary Circulation; Dogs; Female; Heart Failure; Hemodyna | 1989 |